Q-omics provides the consensus-scored ARL15 profile across patient tissues and cancer cell-line models. ARL15 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, ARL15 is differentially expressed in 12, with the highest sampling consensus in KIRP. Additionally, ARL15 protein abundance shows 24,684 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, KIRP, and GBM as cancer lineages where ARL15 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ARL15 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ARL15 survival associations across molecular data types. ARL15 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (6) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ARL15 RNA expression–survival associations across cancer types. High ARL15 expression shows unfavorable associations in UVM, KIRP and UCS, but favorable associations in KIRC, LUSC and PAAD. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for ARL15 RNA expression.
This table summarizes ARL15 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 3. The strongest signals are observed in LIHC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for ARL15. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ARL15 shows lower tumor expression in KIRP, LUAD and KIRC and higher tumor expression in LIHC, HNSC and STAD. The KIRP box plot shows higher ARL15 RNA expression in normal versus tumor tissue (log2 FC = −1.248, t-test p < 0.001).
This table shows molecular features associated with ARL15 in patient tissues and cancer cell lines. In patient samples, ARL15 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, ARL15 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in OESOPHAGUS and BLOOD_Leukemia.
